Products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC20129	AZD3229 Featured	AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
DC12265	AZD3229 Tosylate	AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
DC9946	Lanabecestat(AZD3293,LY-3314814)	AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease.
DC7074	AZD-3463 Featured	AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
DC5013	AZD3514	AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression.
DC8472	AZD-3759 Featured	AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity.
DC8400	AZD3839 Featured	AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
DC9263	AZD-3965 Featured	AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM.
DC8060	AZD-3988	AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM).
DC20725	AZD 4017	AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM).
DC23282	AZD 4320	AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.
DC1075	AZD4547 Featured	AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively.
DC11295	AZD-4573	AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.
DC10739	AZD4635 Featured	AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.
DC23436	AZD-4818	AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner.
DC10773	AZD5069 Featured	AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD.
DC10288	AZD5153 6-Hydroxy-2-naphthoic acid Featured	AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.
DC10774	AZD5153 Featured	AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.
DC20727	AZD-5248	AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1)..
DC7368	AZD5363 Featured	AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM).
DC7369	AZD5438 Featured	AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6.
DC20716	AZD5576	AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM.
DC8232	AZD5582 Featured	AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively).
DC7075	AZD-5597	AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.
DC22009	AZD5718 Featured	AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo.
DC20728	AZD-5718	AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor..
DC22007	AZD5904	AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat.
DC12553	AZD6088	AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM..
DC1069	AZD6244 (Selumetinib,ARRY-142886) Featured	AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM.
DC8004	AZD6482 Featured	AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ.

Products

Customized Consultation X

Your information is safe with us. * Required Fields.